主页文献库搜索
Efficacy of erlotinib in patients (pts) with advanced non-small-cell lung can...

Allan(S G),Bosquee(L),Franke(A),Pirker(R),... J Clin Oncol 0000-00-00

...mos while group 5 had median OS of 5.58 mos, i.e. no difference between male and female C/FS with SqCC. Among pts with n...

Randomized phase III trial of paclitaxel/carboplatin with or without PF-35126...

Hirsh(V),Boyer(M),Rosell(R),Benner(R J),Re... J Clin Oncol 0000-00-00

...mos on PC+PF-676, 4.4 mos on PC) was noted for the addition of PF-676. Many pts in the PF-676 arm experienced mild/moder...

Response to second-line chemotherapy in patients with hormone refractory pros...

Oh(W K),Manola(J),Babcic(V),Harnam(N),Kant... J Clin Oncol 0000-00-00

...mos, respectively (p=.96). Multivariable analysis indicated that age and time from diagnosis to chemo did not influence ...

Contemporary results of permanent prostate seed implantation (PPI) versus con...

Roach(M),Shinohara(K),Weinberg(V),Speight(... J Clin Oncol 0000-00-00

...mos the 5 yr bNED estimate for the pts treated with PPI was 91% (95% CI: 87%-95%). Sixty-eight percent of pts achieved a...

A phase II trial of accelerated radiotherapy using weekly stereotactic confor...

Cardinale(R),Won(M),Choucair(A),Gillin(M),... J Clin Oncol 0000-00-00

...mos. compared to 11.3 mos. for historic controls (p=0.15). Patients with gross total resection (41%) had a MST of 16.1 m...

Health-related quality of life in unresectable hepatocellular carcinoma (HCC)...

Steel(J L),Olek(M),Carr(B I) J Clin Oncol 0000-00-00

...mos follow-up. Pts in both treatment groups reported significant improvement in emotional well-being at 3-mos follow-up ...

Final results of a multicentre phase II trial of high-dose methotrexate (HD-M...

Ferreri(A J),Dell'oro(S),Foppoli(M),Brande... J Clin Oncol 0000-00-00

...mos. 24 pts experienced failure, with a 3-yr FFS of 41±8%. 16 pts are alive, with a median f-up of 36 mos (13-56), and a...

Hypofractionated accelerated high-dose radiotherapy (RT) in non-small cell lu...

Brennan(S M),Fitzpatrick(D),Armstrong(J),M... J Clin Oncol 0000-00-00

...mos, median TTLP =21 mos, and median TTDP = 11 mos. 1 yr PFS=81%, 3 yr PFS=28%. Median OS=17 mos with 1 yr OS=81%, 3 yr ...

Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest rad...

Mina(L A),Neubauer(M A),Ansari(R H),Govind... J Clin Oncol 0000-00-00

...mos (5% 2-sided alpha, 80% power). Accrual reached 243 pts; however the DSMB recommended early termination, after analys...

Prospective comparison of postoperative quality of life (QOL) in patients und...

Park(B J),Ishill(N M),Flores(R M),Gawiak(C... J Clin Oncol 0000-00-00

...MOS SF-36.,VATS for lobectomy in early stage NSCLC resulted in shorter length of stay and significant improvements in im...

上一页 682 683 684 685 686 687 688 689 690 下一页 686 / 共 704

联系地址

山东省济南市章丘区文博路2号

齐鲁师范学院 genelibs生信实验室

山东省济南市高新区舜华路750号

大学科技园北区F座4单元2楼

电话: 0531-88819269

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。


商务邮箱

E-mail: [email protected]